Opinion
Video
Treatment Response to PPAR Agonists and Other Therapies in PBC
Key Takeaways
- PBC involves autoimmune-mediated destruction of intrahepatic bile ducts by autoreactive T lymphocytes, leading to cholestasis.
- Accumulation of toxic bile acids due to cholestasis causes hepatocellular damage and inflammation.
The panel of experts discuss how to determine the effectiveness of treatment in primary biliary cholangitis (PBC), focusing on key clinical markers, biochemical responses, and patient outcomes.
Video content above is prompted by the following:
- How do you determine if treatment is effective in PBC?
Related Videos
Related Content
